Go Pro
NASDAQ:STIM

Neuronetics Q2 2026 Earnings Report

Neuronetics logo
$1.76 +0.10 (+6.02%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$1.75 -0.01 (-0.57%)
As of 07/10/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuronetics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.11
Beat/Miss
N/A
One Year Ago EPS
N/A

Neuronetics Revenue Results

Actual Revenue
N/A
Expected Revenue
$40.09 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuronetics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 4, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Neuronetics Earnings Headlines

Neuronetics (NASDAQ:STIM) Cut to "Sell" at Wall Street Zen
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
See More Neuronetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuronetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuronetics and other key companies, straight to your email.

About Neuronetics

Neuronetics (NASDAQ:STIM) is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings.

Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.

View Neuronetics Profile